Royal Bank of Canada Grows Position in Takeda Pharmaceutical Co. $TAK

Royal Bank of Canada raised its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 11.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 614,851 shares of the company’s stock after acquiring an additional 60,725 shares during the period. Royal Bank of Canada’s holdings in Takeda Pharmaceutical were worth $11,386,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Quantinno Capital Management LP raised its holdings in shares of Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the last quarter. Compound Planning Inc. grew its position in Takeda Pharmaceutical by 30.5% in the 1st quarter. Compound Planning Inc. now owns 59,618 shares of the company’s stock worth $1,104,000 after purchasing an additional 13,945 shares in the last quarter. Keebeck Wealth Management purchased a new stake in Takeda Pharmaceutical in the 1st quarter valued at about $234,000. Finally, Sei Investments Co. increased its stake in Takeda Pharmaceutical by 20.3% in the 1st quarter. Sei Investments Co. now owns 229,943 shares of the company’s stock valued at $4,259,000 after buying an additional 38,740 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 2.6%

Takeda Pharmaceutical stock opened at $17.46 on Friday. Takeda Pharmaceutical Co. has a twelve month low of $12.99 and a twelve month high of $18.90. The firm has a 50 day moving average price of $16.35 and a 200-day moving average price of $17.10. The company has a market capitalization of $55.95 billion, a P/E ratio of 51.36 and a beta of -0.08. The company has a quick ratio of 0.60, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $6.90 billion for the quarter. As a group, equities analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Takeda Pharmaceutical has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.